Завершено
Фаза III
Россия
Placebo; 2400mg SPN-804; 1200mg SPN-804 · Supernus Pharmaceuticals, Inc.
Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures